Patients at high risk - including those with cancer, diabetes, and cardiovascular disease - will be covered under the Pre-Existing Condition Insurance Plan (PCIP) until March 31, thanks to a decision this week from the Department of Health and Human Services.
Patients at high risk — including those with cancer, diabetes, and cardiovascular disease — will be covered under the Pre-Existing Condition Insurance Plan (PCIP) until March 31, thanks to a decision this week from the Department of Health and Human Services.
The PCIP program was originally due to end on December 31, 2013 based on the concept that plans under the Affordable Care Act would no longer exclude participants with pre-existing conditions from coverage. The Obama administration said it would extend the program to ensure high-risk consumers were covered, especially because of the frustrations with Healthcare.gov as well as other missteps in the exchange plan rollout.
"Today's announcement ensures that people with pre-existing conditions such as a history of cancer have life-saving coverage under the Pre-Existing Condition Insurance Plan through the end of open enrollment," said Steve Weiss, senior director, communications and media advocacy for the American Cancer Society Cancer Action Network, Inc. "The extension gives cancer patients and others who had no health insurance options before enrolling in PCIP extra time to choose a marketplace plan that works best for them and their families."
A bill pending lawmaker submission could also help the chronically ill, especially those enrolled in Medicare. Senator Ron Wyden of Oregon and 3 other Congressional leaders said that the Better Care, Lower Cost Act of 2014 would complement the Accountable Care Organization (ACO) model. Unlike an ACO, the Better Care Program (BCP) would allow providers to actively target and enroll the sickest patients. BCPs would also allow providers to tailor plans to patients’ individual needs and conditions.
In 2010, an estimated 70% of Medicare beneficiaries suffered from 2 or more chronic conditions which accounted for nearly 93% of Medicare spending.
In June, Senator Wyden presented at the ACO Summit in Washington, DC. He said, “Washington has been stuck for ages in tired, circular Medicare debates about increasing premiums on the wealthy and raising the age of eligibility. Those are important issues. They do not, however, reform the healthcare delivery system for the sickest seniors. That ought to be a priority for the days ahead.”
Around the Web
Program to Cover Major Illnesses Is Extended [The NY Times]
Bill Would Encourage Team-based Care for Medicare's Chronically Ill [Modern Healthcare]
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More